TipRanks
AC Immune SA (DE:IMR)
FRANKFURT:IMR
Germany Market
IMR
AC Immune SA
RESEARCH TOOLSreports

AC Immune SA (IMR) Stock News & Sentiment

1 Followers
AC Immune Adds Tom Graney to Board Following Extraordinary General Meeting
Premium
Company Announcements
AC Immune Adds Tom Graney to Board Following Extraordinary General Meeting
11d ago
6K
ACIU
Fein Reiterates Buy on AC Immune as VacSYn Phase 2 Data Validate Platform; $12 Price Target Maintained
Premium
Ratings
Fein Reiterates Buy on AC Immune as VacSYn Phase 2 Data Validate Platform; $12 Price Target Maintained
19d ago
ACIU
AC Immune Posts Strong Week-100 Phase 2 Data for Parkinson’s Vaccine ACI-7104
Premium
Company Announcements
AC Immune Posts Strong Week-100 Phase 2 Data for Parkinson’s Vaccine ACI-7104
20d ago
6K
ACIU
AC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to Board
Premium
Company Announcements
AC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to Board
1M ago
6K
ACIU
AC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus
Premium
Company Announcements
AC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus
1M ago
ACIU
Stifel’s Thomas Shrader Reiterates Buy on AC Immune, Citing Diversified Neuroscience Pipeline, Promising NLRP3 Data, and Strong Cash Runway
Premium
Ratings
Stifel’s Thomas Shrader Reiterates Buy on AC Immune, Citing Diversified Neuroscience Pipeline, Promising NLRP3 Data, and Strong Cash Runway
2M ago
ACIU
AC Immune posts positive first‑in‑human data for NLRP3 inhibitor ACI‑19764
Premium
Company Announcements
AC Immune posts positive first‑in‑human data for NLRP3 inhibitor ACI‑19764
2M ago
6K
ACIU
More DE:IMR News >

IMR News on the Web

Fein Reiterates Buy on AC Immune as VacSYn Phase 2 Data Validate Platform; $12 Price Target Maintained
TipRanks News
Bullish
AC Immune AG Part 1 of VacSYn Phase 2 trial Conference Call Transcript
GuruFocus News
Neutral
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
Zacks
Neutral
TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome
Zacks
Neutral
AC Immune posts positive first‑in‑human data for NLRP3 inhibitor ACI‑19764
TipRanks News
Neutral
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
Zacks
Neutral
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
Zacks
Neutral
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Niagen Bioscience (NAGE) and AC Immune SA (ACIU)
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average12.75 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:IMR’s Media Buzz Sentiment?
Currently, no data Available
What is DE:IMR’s weekly average amount of articles?
In an average week, 12.75 articles about DE:IMR are published.
    What is DE:IMR’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    IQVIQVIA Holdings
    GILDGilead Sciences
    ABBVAbbVie
    VRTXVertex Pharmaceuticals
    NVSNovartis
    Showing the stocks with the most bullish news sentiment over the past week